API Regulatory Starting Materials

11-12 May 2017, Copenhagen, Denmark

Course No. 15868

header-image

Speakers

Marieke van Dalen, AspenOss

Hiltrud Horn, Horn Pharmaceutical Consulting, Germany

Gerd Jilge, Boehringer Ingelheim, Germany

Dr Corina Nachtsheim, Quality Assessor, Germany

Matthias Schneider, BASF, Germany

Francois Vandeweyer, Jansse Pharmaceutica, Belgium

Objectives

During this course all relevant aspects regarding API regulatory starting materials will be discussed. You will learn

  • What has to be considered when a starting materials have to be defined
  • How risk assessment can be applied
  • Which aspects have to be taken into account when applying for a CEP
  • How quality agreements should look like
  • How post approval changes can be handled and
  • How impurities in starting materials can be controlled
Furthermore you will have the opportunity to participate in one of two parallel workshops about
  • How to define suitable starting materials in API synthesis
  • How to defend the choice of the starting material in the submission

Background

According to EU GMP Guide Part II (ICH Q7) an API starting material is a raw material, an intermediate, or an API that is used in the production of an API and is incorporated as a significant structural fragment into the structure of the final API. From this point on, appropriate GMP has to be applied to the API manufacturing steps.

In a marketing authorisation application the applicant has to describe in an ASMF the API manufacturing process. The “API regulatory starting material” has to be clearly designated and the rationale for the point at which the production of the API begins has to be documented. The same applies for a CEP application procedure.

In the last few years assessors have been more and more challenging the proposed regulatory starting materials. E.g. the definition of a starting material has been one of the top deficiencies in CEP applications. This is partly due to the fact that companies tend to describe shorter synthetic routes starting from complex starting materials. Moreover changes of critical quality attributes and the request from the authorities to re-define the starting material can create difficult situations regarding additional efforts and significant delays in the application process.

Target Group

This course is designed for all persons involved in the manufacture of APIs. Furthermore, the seminar will be of interest to personnel from quality assurance, regulatory affairs both from API and pharmaceutical companies and to contract manufacturers.

Workshops

  • API synthesis: How to define suitable Starting Materials
  • How to defend the choice of the Starting Material in the submission

Programme

How to define API Regulatory Starting Materials: What do the guidelines tell us?

  • API Regulatory Starting Materials – overview of guidelines
  • Definition according to the guidelines
  • Global guidelines (ICH Q7 and Q11)
  • US, EU and Japan guidance
  • How to use the term “significant structural fragment”
  • Distinguishing starting meterials from raw materials, reagents and solvent
  • Selection of an appropriate Starting Material
  • Starting Material specification
API Regulatory Starting Materials – Challenges and practical implications for a submission
  • How to use the elements of the guidelines in practice
  • Is a global approach the best way forward?
  • What is the level of detail to be provided?
  • What are the consequences of the choice?
API Regulatory Starting Materials – What is different for Generics?
  • One file fits all?
  • Redefinition of the RSM; practical aspects
  • Practical experiences
Starting Materials and the CEP application procedure
  • Regulatory background
  • Scope of the CEP procedure
  • Provisions of the Guideline PA/PH/CEP (14) 06 “Use of a CEP to describe a starting material in an application for another CEP“
  • Important points to be considered for defining an API starting materials
How to handle post-approval changes
  • Changes to the pre-starting material information
  • Re-definition of the starting material: possible or not
  • Handling changes/variations when multiple stakeholders are involved
From starting materials to APIs: risk assessment and criticality analyses
  • Criticality analysis methods (HAZOP, FMEA etc)
  • Critical quality attributes (CQA) and critical process steps (CPS)
  • Linking CQA and synthesis steps
  • Critical impurities
  • Critical raw materials
  • Process criticality analysis; example
Appropriate controls for Starting Materials manufacturers
  • How to control impurities in a starting material
  • Analytical techniques
  • Optimisation of chromatographic methods
  • Downstream experiments
  • Validation of analytical procedures
  • Qualification of Starting Materials
APIC’s position on Starting Materials
  • Definition of the SM
  • Risk management
  • Qualification of the SM supplier
  • Pre-SM information
  • Handling changes/variations

stop

This course is part of the GMP Certification Programme "ECA Certified API Production Manager" Learn more

This training/webinar cannot be booked. Send us your inquiry by using the following contact form.

To find alternative dates for this training/webinar or similar events please see the complete list of all events.

For many training courses and webinars, there are also recordings you can order and watch any time. Just take a look at the complete list of all recordings.

* also payable by credit card
American Express Visa Mastercard

icon
Further dates on-site
Further dates on-site
Not available
icon
Further dates online
Further dates online
Not available
icon
Recording
Not available

Do you have any questions?

Please contact us:
Tel.: +49 6221 8444-0
E-Mail: info@gmp-compliance.org

Woman with headset

Go back

Testimonials about our courses and conferences

“Fantastic course – I really enjoyed the interactive structure & greatly appreciate social activity.”

Anthony Cummins, Sebela Pharmaceuticals, Ireland
GMP Auditor Practice, September 2023

 

“Very well organized, information on point without being overwhelming.”

Eleni Kallinikou, Pharmathen
Live Online Trainng - Pharmaceutical Contracts - Febuary 2024

 

“Good overview of different types of agreements, good to see both the GMP and the legal angle”

Ann Michiels, Johnson&Johnson
Live Online Trainng - Pharmaceutical Contracts, Febuary 2024

 

 

“Well prepared presentations and good presenters. I also like the way of asking questions.”

Alexandra Weidler, Hookipa Biotech GmbH, Austria
Live Online Training – QP Education Course Module A, November 2023